Lyric Bio is pioneering the future of biomanufacturing using proven and proprietary 3D bioprinting and tissue engineering technologies. High cell densities of human tissue-like cultures enable scalable production of human donor-derived therapies in vitro at a fraction of the cost. Lyric Bio’s first product takes aim at a supply limited $20B global market entirely reliant on human donation, IVIg.